RxDoctor Payments Data

Pamela Hitt, NP

Family · Clemson, SCNPI 1003336488

Payments from drug & device makers

$2,701in general payments, 2019–2025

Across 88 payments — averaging $30.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$746
  • Otsuka America Pharmaceutical, Inc.$361
  • Akebia Therapeutics Inc$338
  • Novo Nordisk$221
  • Bayer$173
  • Vifor Pharma, Inc.$172
  • plus $690 from 11 others

What the payments were for

  • Food & beverage$2,67699%
  • Education$251%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,701 in reported general payments places this provider in the 80th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$89,208
Medicare patients
536
Services billed
3,111

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol110$79,811
JardianceEmpagliflozin39$41,852
Torsemide32$1,174
Hydralazine Hcl33$1,037
Bumetanide22$985
Lisinopril65$489
Losartan Potassium68$471
Furosemide123$445
Potassium Citrate ErPotassium Citrate12$439
Amlodipine Besylate91$355
Metoprolol Succinate23$288
Carvedilol42$207
Calcium Acetate11$207
Clonidine Hcl14$119
Prednisone15$88

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$746$79,811110 claims
Boehringer IngelheimJardiance$87$41,85239 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,248 family providers in South Carolina.

Other family in Clemson

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →